GLP-1 Medications

Experiencing sulfur burps or a "stuck" feeling on Ozempic? Dr. Joshua Silva, MD explains the science of delayed gastric emptying and offers 6 actionable tips to reduce gas and bloating.

Retatrutide is an investigational weight-loss medication often described as a “GLP-3.” This article explains what it is, how it works, how it compares to semaglutide and tirzepatide, safety considerations, FDA status, and whether patients should wait or start treatment now.

A physician-written guide explaining who should avoid or use caution with GLP-1 and GLP-1/GIP weight-loss medications like semaglutide and tirzepatide.

Older adults enjoying the benefits of weight loss and eating healthy while using GLP-1 medications (semaglutide or tirzepatide) for safe weight loss, heart health, and muscle and bone support.

What GLP-1/GIP medications really do for inflammation — and what they don’t. A clear, evidence-based guide for patients.

Semaglutide and tirzepatide can significantly improve insulin resistance, hormones, and weight in women with PCOS. Learn what clinical research shows—and whether these medications may be right for you.

If you’re comparing  Zepbound (tirzepatide, GLP-1/GIP) vs. Wegovy (semaglutide, GLP-1)  for weight loss, you’re not alone. These two medications are the most effective  weight-loss injections  available today — and both can help you lose significant weight safely under physician supervision. This guide breaks down how each medication works, how they differ, which one produces more weight loss, what side effects to expect, and how to choose the option that fits your goals, bud

Oral semaglutide (Wegovy® tablets) is now FDA-approved for chronic weight management. This once-daily 25 mg pill uses the same active ingredient as injectable Wegovy®, offering a needle-free option for patients who can’t tolerate injections or prefer a daily tablet. Learn how it works, how it compares to Wegovy® injections, and what this new approval means for access, dosing, and real-world weight-loss results.

Wegovy (semaglutide) is now FDA-approved for MASH with fibrosis (F2–F3) in adults. See what this means for treatment, eligibility, and weight management.

Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD As of 2026, compounded semaglutide and tirzepatide are no longer broadly permitted in the United States. Following resolution of nationwide shortages, the FDA ended its temporary enforcement discretion, meaning these medications may now only be compounded under  limited, legally defined circumstances .¹–³ On  February 21, 2025 , the  U.S. Food and Drug Administration  formally declared the

Wegovy (semaglutide) is FDA-approved to reduce major heart risks in adults with obesity/overweight and cardiovascular disease. Learn what it means and who qualifies.